Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5Pain 4Peripheral Nervous System Diseases 3Neurotoxicity Syndromes 2Colorectal Neoplasms 2Urinary Incontinence 1Prostatic Neoplasms 1Neoplasms 1Musculoskeletal Pain 1Hematologic Neoplasms 1Glioblastoma 1Emergence Delirium 1Drug-Related Side Effects and Adverse Reactions 1Depression 1Cancer Pain 1CIPN 1Acute Pain 1

Interventions

Therapeutics 29Psychiatric Rehabilitation 20Cognitive Behavioral Therapy 12Early Intervention, Educational 10Psilocybin 9Ketamine 9Methods 8Saline Solution 7Yoga 6Surveys and Questionnaires 6Mindfulness-Based Cognitive Therapy 6Esketamine 6Counseling 6Psychosocial Intervention 5Mindfulness 5Methylphenidate 5Educational Status 5Behavior Therapy 5Acupuncture Therapy 5Interviews as Topic 4Exercise Therapy 4Exercise 4Escitalopram 4Control Groups 4Caregivers 4Psychotherapy 3Palliative Care 3Niacin 3Mindfulness-Based Stress Reduction 3Melatonin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Depression × Duloxetine Hydrochloride × Clear all
NCT02443194 2015-12-03

The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Tel-Aviv Sourasky Medical Center

Phase 3 Terminated
50 enrolled
CNS

Depression, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡